Claims
- 1. A method of sensitizing a eukaryotic cell to a therapeutic agent, comprising:
applying at least one electric field pulse to a plurality of cells, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, to produce one or more sensitized cells; and applying one or more therapeutic agents to said one or more sensitized cells, wherein the effect of said one or more therapeutic agents is enhanced in said one or more sensitized cells.
- 2. The method of claim 1, wherein said pulse duration is less than about 1 nanosecond.
- 3. The method of claim 1, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 4. The method of claim 1, wherein said one or more therapeutic agents consists of at least one of the following: nucleic acids, polypeptides, viruses, enzymes, vitamins, minerals, antibodies, vaccines and pharmaceutical agents.
- 5. The method of claim 4, wherein said pharmaceutical agent is a chemotherapeutic compound.
- 6. A method of sensitizing a eukaryotic cell to a therapeutic method, comprising:
applying at least one electric field pulse to a plurality of cells, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, to produce one or more sensitized cells; and applying one or more therapeutic methods to said one or more sensitized cells, wherein the effect of said one or more therapeutic methods is enhanced in said one or more sensitized cells.
- 7. The method of claim 6, wherein said pulse duration is less than about 1 nanosecond.
- 8. The method of claim 6, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 9. The method of claim 6, wherein said one or more therapeutic methods consists of the group consisting of: photodynamic therapy, radiation therapy and vaccine therapy.
- 10. A method of regulating transcription of a gene in a eukaryotic cell, comprising:
selecting at least one gene selected from the group consisting of ASNS, CHOP, CLIC4, CD45, CD53, p36, CD58, AICL FOS, FOSB, DUSP1, JUN, TOB2, GADD34, CLK1, HSPA1B, JUND, EGR1, CACNA1E, CD69 and ETR01; and applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds.
- 11. The method of claim 10, wherein said pulse duration is less than about 1 nanosecond.
- 12. The method of claim 10, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 13. A method of regulating transcription of a gene in a eukaryotic cell, comprising:
selecting at least one gene selected from the group consisting of ITPKA, AHNAK, EMP3, ADORA2B, POU2AF1, AIM1, ATP1G1, ASNS, ETS2, CD45, VIM, TGIF, LAT, CLIC4, SLC7A5, ZFP36L2, RUNX1, SLC3A2, IFRD1, and PrP; and applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds.
- 14. The method of claim 13, wherein said pulse duration is less than about 1 nanosecond.
- 15. The method of claim 13, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 16. A method of regulating transcription of a gene in a eukaryotic cell, comprising:
selecting at least one gene selected from the group consisting of cell-cycle control genes, stress-response genes and immune response genes; and applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds.
- 17. The method of claim 16, wherein said pulse duration is less than about 1 nanosecond.
- 18. The method of claim 16, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 19. A method of regulating transcription of a gene in a eukaryotic cell, comprising:
selecting at least one gene to be regulated; and applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, thereby regulating said at least one gene.
- 20. The method of claim 19, wherein said pulse duration is less than about 1 nanosecond.
- 21. The method of claim 19, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 22. The method of claim 19, wherein said at least one gene is selected from the group consisting of: ASNS, CHOP, CLIC4, CD45, CD53, p36, CD58, AICL FOS, FOSB, DUSP1, JUN, TOB2, GADD34, CLK1, HSPA1B, JUND, EGR1, CACNA1E, CD69 and ETR01.
- 23. The method of claim 19, wherein said at least one gene is selected from the group consisting of: ITPKA, AHNAK, EMP3, ADORA2B, POU2AF1, AIM1, ATP1G1, ASNS, ETS2, CD45, VIM, TGIF, LAT, CLIC4, SLC7A5, ZFP36L2, RUNX1, SLC3A2, IFRD 1, and PrP.
- 24. The method of claim 19, wherein the at least one electric field pulse is greater than 10 kV/cm.
- 25. A method of determining induction of gene transcription in response to electropertubation, comprising:
suspending a plurality of cells in a medium; applying at least one electric field pulse to said plurality of cells, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds; identifying at least one cell which is electroperturbed; isolating said electroperturbed cell; and determining cellular gene transcription in said electroperturbed cell.
- 26. The method of claim 25, wherein the electroperturbed cell is identified based upon cellular morphology or cellular biochemistry.
- 27. The method of claim 25, wherein the electroperturbed cell is identified using fluorescent staining.
- 28. A method of marking a eukaryotic cell for diagnostic or therapeutic procedures, comprising:
suspending a plurality of cells in a medium; electroperturbing said plurality of cells, thereby inducing a cellular response in at least a portion of the cells, wherein said cellular response marks said at least a portion of the cells for a diagnostic or therapeutic procedure; and identifying said at least a portion of the cells that were electroperturbed by the presence of said cellular response.
- 29. The method of claim 28, wherein said electroperturbing comprises applying at least one electric field pulse to said plurality of cells, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds.
- 30. The method of claim 28, wherein said marking comprises affecting one or more characteristics of the cell, said characteristic selected from the group consisting of: gene transcription, gene translation, protein synthesis, post-translational modifications, protein processing, cellular biosynthesis, degradative metabolism, cellular physiology, cellular biophysical properties, cellular biochemistry and cellular morphology.
- 31. The method of claim 28, wherein said diagnostic or therapeutic procedure comprises lysing the cell.
- 32. The method of claim 28, wherein said cellular response comprises the translocation of at least one membrane component of an intracellular membrane of said cell.
- 33. The method of claim 32, wherein said one membrane component is a phospholipid or a protein.
- 34. The method of claim 33, wherein said phospholipid is phosphatidylserine.
- 35. The method of claim 28, wherein said cellular response comprises the disruption of least one intracellular structure without substantially affecting the external membrane of the cell.
- 36. The method of claim 35, wherein said at least one intracellular structure is selected from the group consisting of: nucleus, mitochondria, storage vacuoles, endoplasmic reticulum compartments, cytoplasmic stores and cytoskeletal-membrane attachments.
- 37. A method of disrupting an intracellular membrane of a eukaryotic cell, comprising:
applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, thereby inducing disruption of the intracellular membrane.
- 38. The method of claim 37, wherein said intracellular membrane is selected from the group consisting of: cytoplasmic membrane, nuclear membrane, mitochondrial membrane and segments of the endoplasmic reticulum.
- 39. The method of claim 37, wherein said pulse duration is less than about 1 nanosecond.
- 40. The method of claim 37, wherein said disruption of the intracellular membrane comprises translocating at least one membrane component.
- 41. The method of claim 40, wherein said membrane component is a phospholipid or protein.
- 42. The method of claim 41, wherein said phospholipid is phosphatidylserine.
- 43. The method of claim 37, wherein the at least one electric field is greater than 10 kV/cm.
- 44. A method of marking a eukaryotic cell for phagocytosis, comprising:
suspending a plurality of cells in a medium; applying at least one electric field pulse to said plurality of cells, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, thereby inducing a cellular response in at least a portion of said cells, wherein said cellular response marks said cells for phagocytosis.
- 45. The method of claim 44, wherein said cellular response comprises translocating at least one membrane component.
- 46. The method of claim 45, wherein said membrane component is a phospholipid or protein.
- 47. The method of claim 46, wherein said phospholipid is phosphatidylserine.
- 48. A method of disrupting one or more intracellular structures of a eukaryotic cell, comprising:
applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, thereby inducing disruption of at least one intracellular structure, without substantially affecting the external cell membrane.
- 49. The method of claim 48, wherein said at least one intracellular structure is selected from the group consisting of: nucleus, mitochondria, storage vacuoles, endoplasmic reticulum compartments, cytoplasmic stores and cytoskeletal-membrane attachments
- 50. A method of determining cellular tolerance to electropertubation, comprising:
(a) suspending one or more cells in a medium; (b) applying a first electric field pulse to one or more cells, (c) identifying electroperturbed cells; (d) isolating said electroperturbed cells; (e) identifying one or more indicators of cellular response in said electroperturbed cells; (f) applying a second electric field pulse to one or more cells; (g) repeating steps (c)-(e) (h) comparing said one or more indicators of cellular response after application of the first electric field with said one or more indicators of cellular response after application of the second electric field.
- 51. The method of claim 50, wherein said second electric field is not equal to said first electric field.
- 52. The method of claim 50, wherein said one or more indicators of cellular response is selected from the group consisting of changes in: gene transcription, gene translation, protein synthesis, post-translational modifications, protein processing, cellular biosynthesis, degradative metabolism, cellular physiology, cellular biophysical properties, cellular biochemistry and cellular morphology.
- 53. A method of selectively electroperturbing a population of cells, comprising:
determining a dielectric property of one or more cells in a first sub-population of cells; determining a dielectric property of one or more cells in a second population of cells; determining an electric field pulse based on said dielectric property of said first sub-population of cells and said dielectric property of said second population of cells, wherein said electric field pulse selectively electroperturbs the first sub-population of cells without substantially affecting the second population of cells. obtaining a cell suspension, wherein said cell suspension contains said first sub-population of cells and said second population of cells; and applying said electric field pulse to said cell suspension, thereby electroperturbing said first sub-population of cells without substantially affecting the second population of cells.
- 54. The method of claim 53, wherein said first sub-population of cells comprises rapidly dividing cells and wherein said second population of cells comprises terminally differentiated cells.
- 55. The method of claim 53, wherein said first sub-population of cells comprises a first type of rapidly dividing cell and wherein said second population of cells comprises a second type of rapidly dividing cell.
- 56. The method of claim 53, wherein said electroperturbing induces changes in cellular response, wherein said cellular response is selected from the group consisting of: gene transcription, gene translation, protein synthesis, post-translational modifications, protein processing, cellular biosynthesis, degradative metabolism, cellular physiology, cellular biophysical properties, cellular biochemistry and cellular morphology.
- 57. The method of claim 54, wherein said rapidly dividing cells are tumorigenic cells.
- 58. The method of claim 54, wherein said terminally differentiated cells are non-tumorigenic cells.
- 59. A method of selectively regulating gene transcription in rapidly dividing cells, comprising:
obtaining a cell suspension, wherein said cell suspension contains rapidly dividing cells and terminally differentiated cells; and applying at least one electric field pulse to the cell, wherein each electric field pulse has a pulse duration and intensity sufficient to induce gene transcription primarily only in said rapidly dividing cells.
- 60. The method of claim 59, wherein said rapidly dividing cells are tumorigenic cells.
- 61. The method of claim 59, wherein said terminally differentiated cells are non-tumorigenic cells.
- 62. A method of reducing proliferation of rapidly dividing cells in a patient, comprising;
removing a portion of a patient's tissue, wherein said tissue contains rapidly dividing cells and terminally differentiated cells; applying at least one electric field pulse to one or more cells in said tissue, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds; and reintroducing said tissue into said patient.
- 63. The method of claim 62, wherein said tissue consists of one or more of the following: blood, cerebrospinal fluid, lymphatic fluid and bone marrow.
- 64. The method of claim 62, wherein said rapidly dividing cells are tumorigenic cells.
- 65. The method of claim 62, wherein said terminally differentiated cells are non-tumorigenic cells.
- 66. A method of reducing proliferation of rapidly dividing cells in a patient, comprising;
identifying a target cell population in the patient, wherein said cell population comprises rapidly dividing cells and terminally differentiated cells; applying at least one electric field pulse to at least a portion of said target cell population, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, thereby reducing proliferation of rapidly dividing cells in said target cell population.
- 67. The method of claim 66, wherein said rapidly dividing cells are tumorigenic cells.
- 68. The method of claim 66, wherein said terminally differentiated cells are non-tumorigenic cells.
- 69. The method of claim 66, further comprising applying at least one electric field pulse to at least a portion of said target cell population, wherein each electric field pulse has a pulse duration of more than about 100 nanoseconds.
- 70. A method of treating a tumor in a patient, comprising;
identifying a tumor in the patient; applying a catheterized electrode to said patient proximate to said tumor; wherein said catheterized electrode is capable of providing at least one electric field pulse; and applying said at least one electric field pulse to at least a portion of said tumor, wherein each electric field pulse has a pulse duration of less than about 100 nanoseconds, thereby treating said tumor.
- 71. The method of claim 70, wherein said treating said tumor comprises reducing proliferation of rapidly dividing cells in said tumor.
- 72. The method of claim 70, further comprising applying at least one electric field pulse to at least a portion of said tumor wherein each electric field pulse has a pulse duration of more than about 100 nanoseconds.
- 73. The method of claim 70, wherein said catheterized electrode is coupled to an endoscope.
- 74. The method of claim 70, further comprising applying said catheterized electrode to said patient in conjunction with an endoscopic procedure.
- 75. A method of facilitating entry of a diagnostic or therapeutic agent into a cell's intracellular structures, comprising:
applying at least one first electric field pulse to the cell, said first electric pulse sufficient to cause electroporation; incubating said cell with the therapeutic agent; and applying one or more second electric field pulses to one or more cells in said tissue, wherein each second electric field pulse has a pulse duration of less than about 100 nanoseconds.
- 76. The method of claim 75, wherein said therapeutic agent consists of one or more of the following: nucleic acids, polypeptides, viruses, enzymes, vitamins, minerals, antibodies, vaccines and pharmaceutical agents.
- 77. The method of claim 75, wherein said pulse duration is less than about 1 nanosecond.
- 78. The method of claim 75, wherein said intracellular structure is selected from the group consisting of: nucleus, mitochondria, storage vacuoles, endoplasmic reticulum compartments, cytoplasmic stores and cytoskeletal-membrane attachments
- 79. A method of identifying an effective therapeutic agent, comprising:
applying at least one putative therapeutic agent to at least one cell; and determining whether at least one gene selected from the group consisting of ASNS, CHOP, CLIC4, CD45, CD53, p36, CD58, AICL FOS, FOSB, DUSP1, JUN, TOB2, GADD34, CLK1, HSPA1B, JUND, EGR1, CACNA1E, CD69, ETR01, ITPKA, AHNAK, EMP3, ADORA2B, POU2AF1, AIM1, ATP1G1, ASNS, ETS2, CD45, VIM, TGIF, LAT, CLIC4, SLC7A5, ZFP36L2, RUNX1, SLC3A2, IFRD1, and PrP are up-regulated in said cell, wherein if at least one of said genes is up-regulated, the putative therapeutic agent is identified as an effective therapeutic agent.
- 80. The method of claim 79, wherein said putative therapeutic agent consists of one or more of the following: nucleic acids, polypeptides, viruses, enzymes, vitamins, minerals, antibodies, vaccines and pharmaceutical agents.
- 81. The method of claim 79, wherein said putative therapeutic agent is an anti-proliferation agent.
RELATED APPLICATIONS
[0001] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/336,587, filed on Dec. 4, 2001, herein incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60336587 |
Dec 2001 |
US |